{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:48:24Z","timestamp":1772606904214,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> High dose methotrexate (HDMTX) is used for the treatment of pediatric hemato-oncological diseases. HDMTX can induce acute kidney injury in cases of delayed elimination. The use of leucovorin remains the most effective rescue action. Further treatment options are of difficult access in the rare cases where leucovorin fails to prevent renal failure from occurring. Glucarpidase is an effective treatment in cases of methotrexate (MTX) delayed elimination, but cost is high and availability is limited. Charcoal hemoperfusion (CHP) is a very efficient procedure to remove protein-bound drugs, promoting fast MTX elimination, but is rarely considered as a treatment option.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We present three pediatric cases with prolonged exposure to MTX after HDMTX and delayed elimination in which hemoperfusion was performed as rescue treatment for methotrexate intoxication.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Charcoal hemoperfusion was performed with positive results and no complications as bridging until glucarpidase was available in two cases and in one case where two doses of glucarpidase led to insufficient reduction of MTX levels.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> CHP can be considered as a rescue treatment option in MTX intoxication, since it is an effective and safe extracorporeal method for removing MTX, in cases where rescue with leucovorin is insufficient and glucarpidase is not available or while waiting for delivery.<\/jats:p>","DOI":"10.3389\/fped.2021.635152","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T03:16:58Z","timestamp":1629429418000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available"],"prefix":"10.3389","volume":"9","author":[{"given":"Alejandra","family":"Rosales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Dapena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","article-title":"Methotrexate: clinical pharmacology, current status and therapeutic guidelines","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"26395","DOI":"10.1002\/pbc.26395","article-title":"Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia","volume":"64","author":"Svahn","year":"2017","journal-title":"Pediatr Blood Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hon.2479","article-title":"Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?","volume":"36","author":"Ranchon","year":"2018","journal-title":"Hematol Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/0885066609359592","article-title":"Extracorporeal removal techniques for the poisoned patient: a review for the intensivist","volume":"25","author":"Fertel","year":"2010","journal-title":"J Intensive Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00467-016-3389-2","article-title":"Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity","volume":"31","author":"Chan","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis."},{"key":"B13","first-page":"751","article-title":"Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis","volume":"61","author":"Djerassi","year":"1977","journal-title":"Cancer Treat Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/cpt1978233351","article-title":"Hemoperfusion for methotrexate removal","volume":"23","author":"Gibson","year":"1978","journal-title":"Clin Pharmacol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S0140-6736(86)91528-X","article-title":"Charcoal haemoperfusion and methotrexate toxicity","volume":"1","author":"Bouffet","year":"1986","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0002-9343(87)90085-4","article-title":"Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency","volume":"82","author":"Molina","year":"1987","journal-title":"Am J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/1097-0142(19880901)62:5<884::AID-CNCR2820620506>3.0.CO;2-A","article-title":"Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion","volume":"62","author":"Relling","year":"1988","journal-title":"Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00002018-199005060-00005","article-title":"Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma","volume":"5","author":"Grimes","year":"1990","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000186462","article-title":"Charcoal hemoperfusion and methotrexate toxicity","volume":"58","author":"McIvor","year":"1991","journal-title":"Nephron."},{"key":"B20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/MPH.0b013e318182e73e","article-title":"Early recognition of renal toxicity of high-dose methotrexate therapy: a case report","volume":"30","author":"Nowicki","year":"1998","journal-title":"J Pediatr Hematol Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/08880010902976023","article-title":"Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure","volume":"26","author":"Nemoto","year":"1999","journal-title":"Pediatr Hematol Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ndtplus\/sfr002","article-title":"High-dose continuous venovenous hemofiltration combined with charcoal hemoperfusion for methotrexate removal","volume":"4","author":"Grafft","year":"2011","journal-title":"NDT Plus."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","article-title":"Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma","volume":"102","author":"Landmann","year":"2017","journal-title":"Haematologica."},{"key":"B25","unstructured":"Badell SerraI\n          Tratamiento de la Leucemia Aguda Linfobl\u00e1stica de Nuevo Diagn\u00f3stico, Recomendaciones terap\u00e9uticas LAL\/SEHOP-PETHEMA 2013 Versi\u00f3n 2.0. Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia2014"},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/ndt\/gfw456","article-title":"Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey","volume":"32","author":"Bouchard","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-002-0946-7","article-title":"Effective removal of methotrexate by high-flux hemodialysis","volume":"7","author":"Saland","year":"2002","journal-title":"Pediatr Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist."},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/pbc.25800","article-title":"Reply to: glucarpidase for the treatment of methotrexate-induced renal dysfunction and delayed methotrexate excretion","volume":"63","author":"Scott","year":"2016","journal-title":"Pediatr Blood Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPKorg: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.635152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T03:17:01Z","timestamp":1629429421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.635152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":31,"alternative-id":["10.3389\/fped.2021.635152"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.635152","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"article-number":"635152"}}